More Good News for Neurocrine Biosciences

Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50 
Yesterday, November 2, 2023, Neurocrine Biosciences (NBIX) announced interim results from the KINECT®-HD2 study about INGREZZA® (valbenazine) capsules used for long-term treatment of adults with chorea associated with Huntington's disease (HD). The Interim data suggest that one-capsule, once-daily of INGREZZA improved . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.